Armed with a fresh injection of £25m, the UK's KaNDy is about to begin Phase IIb trials of a dual mechanism therapy it believes will be a transformational treatment to tackle two key symptoms of the menopause, hot flashes and night time awakenings.
KaNDy Therapeutics is pushing its breakthrough non-hormonal treatment for symptoms of the menopause into Phase II trials, boosted by a fresh cash injection and a new high-profile US backer on board.
The UK company has successfully closed a series C financing round, raising £25m from new investor Longitude Capital, and existing supporters Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
An ‘historic economic prosperity deal’ does not include the sector.
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
